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There are four components to the time-dependent “open
vasculature” hypothesis. The achievement of 1) early flow,
2) full microvascular flow, 3) full epicardial flow, and 4)
sustained flow are all related to improved clinical outcomes
in acute myocardial infarction (MI) (1). Pharmacologic
strategies may more fully satisfy the first two criteria (they
rapidly open epicardial vessels and the microvasculature),
but mechanical interventions may better satisfy the latter
two criteria (full and sustained reperfusion). Clinical out-
comes are related not merely to the attainment of one, but
rather to the fulfillment of all four prerequisites of the open
vasculature hypothesis (1). Perhaps “open vasculature hy-
pothesis” is now a more appropriate term than “open artery
hypothesis” because it has been shown that improved
tissue-level perfusion (either on the angiogram [2], the
echocardiogram [3], or the electrocardiogram [4]) is related
to improved clinical outcomes independent of flow in the
epicardial artery. Pharmacologic agents, such as the glyco-
protein 2b3a inhibitors, may improve tissue-level reperfu-
sion in acute MI (4). It would therefore be logical to offer
the best of two complementary strategies by combining the
speed of patency and improved microvascular function
provided by a pharmacologic strategy with the speed of flow
following more definitive (albeit later) mechanical interven-
tion in what has alternatively been called a “JIMI” (Joint
Intervention in Myocardial Infarction)-like approach (1),
“prejunctive” therapy (5), or “facilitated PCI” (6).
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Despite these intuitive benefits, early randomized trials
did not show a clinical benefit of conventional angioplasty
when routinely performed immediately following thrombol-
ysis over thrombolysis alone (7–9). This may have been due
to a higher risk of intramural hemorrhage in the arterial wall
and the ensuing abrupt closure. These trials are now
outdated, having preceded the widespread use of stents,
thienopyridines, and glycoprotein 2b3a inhibitors. Recently,
the PACT study (Primary Angioplasty/Alteplase Compat-
ibility Trial) incorporated these current practice patterns
and demonstrated that half-dose tPA can be safely com-
bined with PCI (percutaneous coronary intervention) (5).
This trial reaffirmed the time-dependent nature of the open
vasculature hypothesis: those patients who had TIMI
(Thrombolysis in Myocardial Infarction trial) flow grade 3
restored early, before PCI, had improved ejection fractions
(62%) compared with those who had delayed restoration of
TIMI flow grade 3 after PCI (58%) (p 5 0.001) (5).
Although stand-alone thrombolytic agents restore normal
blood flow (TIMI flow grade 3) in approximately 60% of
patients, the combination of fibrinolytic agents (which act
upon the fibrin component of the clot) with glycoprotein
2b3a inhibitors (which act upon the platelet component of
the clot that holds the fibrin together) dramatically improves
angiographic efficacy even earlier, by 60 min: normal TIMI
flow grade 3 has been observed in 72% of patients treated
with combination therapy versus 43% in those patients
treated with front-loaded tPA in the TIMI-14 trial (p 5
0.002) (10). Combination therapy also allows the use of
lower doses of thrombolytic agents, which may in turn
potentially reduce the risk of intracranial hemorrhage; and it
combats the prothrombotic state induced by thrombolytic
agents. Thus, glycoprotein 2b3a inhibitors may be well
suited as an adjunct to both thrombolytic and mechanical
interventions in acute MI.
To this end, data from the SPEED trial advances these
efforts by demonstrating that it is safe and efficacious to
perform PCI after either thrombolytic monotherapy or
combination therapy (rPA and abciximab) (6). Like so
many initial efforts in any field, this is a nonrandomized
comparison of early PCI versus no PCI. Considering the
momentum of the open vascular hypothesis, a randomized
comparison of early PCI versus no PCI has historically been
difficult to undertake, because many investigators believe it
is unethical to withhold early PCI. Insofar as it is a
nonrandomized comparison, the SPEED analysis suffers
from the usual limitations of measured (and unmeasured)
imbalances between the two groups as acknowledged by the
investigators.
Early PCI was planned in this trial and was performed in
61% of patients. This is similar to the 61.7% rate of PCI we
observed in the TIMI-14 trial when PCI was not necessarily
encouraged but was performed at operator discretion (10). If
PCI was encouraged in all patients, yet was not performed
in 39% of cases, one must search for reasons why PCI was
not performed. One obvious explanation is that the no-
early-PCI patients had successful thrombolysis with either
TIMI flow grade 3 or, alternatively, a minimal lesion (11) at
the time of angiography. Indeed, more of the patients not
treated with early PCI paradoxically received combination
therapy, which has been associated with higher rates of
TIMI flow grade 3 (10). We have recently shown that
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patients with minimal lesions following thrombolysis have
very favorable outcomes, and this probably does not account
for the poor outcomes in the no early PCI group (11).
It is possible that operators planned to perform PCI not
early, but at a delayed time, perhaps because of lingering
concerns regarding the advisability of this approach or
because of bleeding at the time of initial angiography.
Indeed, there was a higher rate of bleeding and transfusion
in the no-early-PCI group. It is somewhat counterintuitive
that patients in the no-early-PCI group should have had
more bleeding. Procedure times should have been shorter,
catheter sheath sizes should have been smaller, and heparin
and thienopyridines should have been used less often in the
no-early-PCI patients. Again, patients not treated with
early PCI were more likely to receive combination therapy
than were early PCI patients, and this may account in part
for some of the increased bleeding. Perhaps operators that
did not perform PCI were also less likely to use closure
devices and had higher bleeding rates. Or perhaps the
bleeding occurred not at the time of the initial angiography,
but later in the hospital course, when a patient not treated
with early PCI subsequently developed reocclusion and
required reinstrumentation and aggressive anticoagulation.
Another important reason why patients may not have
undergone early PCI is that early angiography may have
identified surgical disease (left main or three-vessel disease)
requiring coronary artery bypass grafting (CABG). Bleeding
associated with CABG would also account for the higher
rates of transfusion in the no-early-PCI arm.
Finally, the no-early-PCI group may have died or sus-
tained adverse outcomes before having the opportunity to
undertake PCI, and this may account in part for why the
angiographic sample sizes are lower in this study arm (136
patients with angiographic infarct artery location data,
whereas 162 patients were in this arm).
The baseline characteristics show that there were more
right coronary arteries in the early-PCI arm, and this may
have contributed to the favorable outcomes in this arm,
which was enriched with inferior MIs. There is no descrip-
tion of disease extent (single-, double-, triple-vessel dis-
ease), lesion complexity (type A, B, C), lesion location
(ostial or bifurcation), lesion length, hemodynamic pertur-
bations (tachycardia or low blood pressure) to permit a
comparison of the two groups. These angiographic and
clinical features greatly influence operator choices in either
performing or not performing early PCI. Unfortunately, no
multivariate model was developed to correct for these
potential imbalances in baseline characteristics.
A total of 43 patients underwent PCI outside the “early”
60-to-90-min window and were excluded from this analysis.
It is difficult to capture or quantitate why a patient under-
goes delayed PCI. Some of these patients may have under-
gone delayed PCI for reocclusion, and if they had been
included among the no-early-PCI group, the results might
have been even less favorable for this cohort. Conversely, if
these delayed PCIs were performed electively as part of a
conservative strategy and had good outcomes, this would
have favorably influenced the results reported for the no-
early-PCI group.
While previous analyses have segregated the approaches
of rescue PCI (artery closed before the procedure) and
adjunctive PCI (artery open before the procedure), this
analysis lumps the two categories together in the primary
analysis. The investigators do substantiate what has been
reported in the past: flow is better if PCI is performed on
open arteries (adjunctive PCI) than on closed arteries
(rescue PCI) after thrombolysis (12,13). Although the
overall strategy of early PCI may have “facilitated” better
clinical outcomes in this nonrandomized analysis, no phar-
macologic regimen was associated with facilitated or im-
proved epicardial flow at the completion of the PCI.
However, it is important to note that there may have been
improvements in microvascular flow that were not mea-
sured. Indeed, we have demonstrated that combination
therapy does improve microvascular perfusion both before
and after PCI with improved ST segment resolution (14).
The advantage of a “facilitated PCI” approach may not be
the flow following the intervention, but rather the fact that
flow was restored prior to the intervention in many cases.
Certainly, the PACT trial has documented that early
restoration of flow prior to intervention is related to im-
proved ejection fractions (5).
Some of the readership may interpret the 86% rate of
TIMI flow grade 3 at the completion of the PCI as
unimpressive compared with that reported in other inter-
ventional trials (15,16). However, we have shown that when
the standard definition of TIMI flow grade 3 is used, this is
about 10 percentage points lower than if a “3 heart beat
definition” for dye to traverse the artery for TIMI flow grade
3 is used in interventional trials (15,16). Thus, to be put on
a par with the results of interventional trials, the post-PCI
86% rate reported by Hermann et al. (6) would translate
into an approximate 96% rate reported for interventional
trials using a “3 heart beat” definition of TIMI flow grade 3
(15,16).
Percutaneous coronary intervention was encouraged in all
cases, and perhaps we should evaluate the results of the
entire trial on an “intent to treat” basis, or “intent to perform
early PCI” basis. In this case, 17 of 485 (3.5%) of the
patients in which there was the intent to perform facilitated
PCI died. This is significantly lower (p 5 0.028) than the
pooled mortality among all patients treated with either
thrombolysis alone (68/1,055 or 6.5%) or primary percuta-
neous transluminal coronary angioplasty (PTCA) (47/1,038
or 4.5%) in all randomized trials of primary PTCA versus
thrombolysis (1,17). Thus, the intent to perform facilitated
PCI, or the strategy as a whole, had a lower mortality than
did prior randomized trials of either thrombolytic mono-
therapy or primary PTCA. If facilitated PCI is viewed as
the totality of modern therapies (early PCI, stents, glycop-
rotein 2b3a inhibitors), then these modern strategies tend to
improve outcomes over older strategies.
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TNK is more fibrin specific than either tPA or rPA; it
tended to reduce intracranial hemorrhage in those .75
years of age (1.72% vs. 2.62%, p 5 0.18) and significantly
reduced bleeding complications and the need for transfu-
sion, compared with tPA in the ASSENT-2 trial (18). The
safety profile of this single-bolus thrombolytic agent may
also allow it to be very efficacious in combination with
glycoprotein 2b3a antagonists and interventional strategies.
Indeed, we have reported that weight optimizing the dose of
TNK significantly improves flow both before and after
interventions and as such “facilitated” post-PCI flow in the
TIMI-10B trial (19). Several combination therapy trials of
reduced-dose TNK in conjunction with glycoprotein 2b3a
inhibitors are now under way: low-dose TNK in conjunc-
tion with abciximab/enoxaparin in ENTIRE and AS-
SENT-3; in conjunction with eptifibatide in INTEGRITI;
and in conjunction with tirofiban in FASTER.
Although the data from the SPEED trial demonstrates
that PCI is both safe and effective after either rPA alone or
in combination with abciximab, a dedicated randomized
trial of PCI versus no PCI is necessary to examine the
benefits combining these approaches. Finally, though the
risk of intracranial hemorrhage does not appear to be
increased with combination therapy in the TIMI-14 and
SPEED trials (10), this preliminary observation requires
further substantiation in much larger trials such as
GUSTO-4 involving approximately 8,000 patients per
study arm before combination therapy can be universally
advocated. Finally, “time is myocardium”: we have recently
demonstrated in over 27,000 primary PTCA patients that
delays in door-to-balloon time for primary PCI are associ-
ated with higher mortality (20), and facilitated PCI may
further improve upon outcomes by speeding the time to
vessel patency (5).
The results of the SPEED analysis add momentum to a
growing body of acute MI literature supporting a “union in
reperfusion”: the use of pharmacologic agents to quickly
open both the artery and the microvasculature and the use of
adjunctive interventions to further improve flow and keep
arteries open.
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